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Introduction
Radical prostatectomy involves removal of the entire prostate gland between the urethra and bladder, and resection of both seminal vesicles, along with sufficient surrounding tissue to obtain negative margins. Often, this procedure is accompanied by bilateral pelvic lymph node (LN) dissection [1] .
Robot-assisted laparoscopic prostatectomy (RALP) is displacing radical retropubic prostatectomy (RRP) as the most used surgical approach for clinically localized prostate cancer (PCa) in the USA and is being increasingly used in Europe and other parts of the world [2] .
The number of involved nodes [3] , the tumor volume within the LN, and capsular perforation of the nodal metastases are predictors of early recurrence after prostatectomy for nodal metastasized PCa [4] .
The fatty tissue overlying the prostate is usually removed in order to have a better exposure of the dorsal venous complex, the puboprostatic ligaments, and the prostate apex [5] . This fatty tissue is examined separately by the pathologist for the presence of LNs and possible metastasis. If this fatty tissue is missed, it might have an impact on the postoperative disease stage, treatment, and oncologic outcomes.
In our study, we evaluated the anterior prostatic fat (APF) tissues that were separately sent for histopathology in order to examine presence of LNs and metastasis. 
Materials and Methods
Overall, 629 consecutive patients who underwent RALP between January 2010 and September 2015 were included in our study. Surgical procedures were performed by 3 robotic surgeons (J.A., T.L. and N.V.). All of the RALP procedures were performed via a transperitoneal approach.
During the RALP procedures, APF tissue samples were sent separately for pathologic evaluation. APF covering prostate, dorsal venous complex, prostatic apex, puboprostatic ligaments, prostate-vesical junction and the bladder neck was dissected en bloc laterally and cephalad.
Parameters including serum prostate specific antigen (PSA), prostate weight and Gleason score were included for further evaluation.
Results
Patient characteristics are summarized in table 1. Mean patient age and serum PSA were 62.2 ± 5.8 years (range 39-76 years) and 8.9 ± 6.2 ng/ml (range 1-42 ng/ ml), respectively. Overall, LNs in APF tissues were detected in 45 (7.1%) patients with a mean LN yield of 1.1 ± 0.7 LNs (range 1-3). Among those found, only 2 patients had positive LN (0.3%).
Patients with LNs in their APF 4 of them in pT3a disease, 7 in pT2c, 2 in pT2b, 22 in pT2a, 9 in pT1c and 1 in pT1a. Patients with positive LNs were pT2c and pT3a, and upgraded on final prostate histopathology to pT3b and pT4. Patients with LNs had Gleason score of 3 + 3 = 6 in 16 patients, 3 + 4 = 7 in 21 patients, 4 + 3 = 7 in 7 patients and only one had Gleason score of 4 + 4 = 8. The 2 patients with LNs had Gleason 3 + 4 and 4 + 3 and upgraded on final prostate pathological evaluation to Gleason 4 + 3 and 4 + 5, respectively.
Discussion
In our study, we identified LNs in APF tissue in 7.1% (n = 629) of the patients. Aning et al. [6] reported 17% (n = 282), Jeong et al. [7] reported 11.6% (n = 228), Finley et al. [8] reported 14.7% (n = 204) and Atmaca et al. [11] reported 10% (n = 129) LNs in APF tissue in their series, respectively. Therefore, our findings are less than all the previously published studies. Our study has longer series of patients 629 done over 5 years.
In our study, metastatic LN was detected in 2 (0.3%) out of 629 patients that was obtained from the APF tissue region overlying the prostate. However, Finley et al. [8] found LN metastasis in 4 of 204 patients and Jeong et al. [7] found LN metastasis in 3 of 228 patients in their series. In the published literature, LN metastasis rate in anterior periprostatic lymphoid tissue varied between 1.2 and 2.5% [7] [8] [9] [10] . In our study, it was only 0.3%. In a multi-center study, Kim et al. [10] Kim et al. [10] suggested that removal of APF tissue leads to more accurate staging of the patients. In their series, due to the identification of metastatic LNs in the APF tissue, 0.63% of the patients were up-staged pathologically [10] . This finding might certainly have an impact on postoperative adjuvant treatment requirement in this patient group.
Involvement of the regional LNs is a very important prognostic indicator of disease-free survival and overall survival in PCa [15] . Metastatic LN is detection in APF tissue might necessitate adjuvant hormone therapy or radiotherapy. In our study, the 2 patients (0.3%) who had the metastatic nodes only one of them needed post operative adjuvant radiotherapy. To assess the need of adjuvant therapy, postoperative serum PSA follow-up is important as well as detecting metastatic LNs. We always perform APF tissue as en bloc excision, while Kim et al. [10] separately evaluated APF tissue in 3 pieces as a left packet, middle packet and a right packet.
In their results, 89% of the LNs were detected in the middle packet [10] . They suggested separately dissecting and sending APF tissue for pathologic evaluation.
Not only robotic prostatectomies have evaluated LN existence in APF tissue but also it was assessed in open RRP series. Hansen et al. [16] identified LNs in periprostatic region in 19 (5.5%) patients of 356 in their RRP series and 4 (1.2%) of them had metastasis. In this study they reported that there is no connection between periprostatic LN metastasis and pelvic LN metastasis, but in order to provide exact staging, pathologic examination of periprostatic lymphatic area should be a routine procedure. Our study we had a fair number of patients only small number of patients (0.3%) showed metastatic nodes in the APF tissue. With increasing number of patients and having more high-risk PCa patients, we think more patients with metastatic LNs in the APF tissue might be identified.
Conclusion
There appears to be lymphatic drainage to the anterior prostatic fat from the prostate. Hence APF should be included in pelvic LN dissection templates when lymphadenectomy is contemplated in patients undergoing radical prostatectomy.
